[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2024165571A3 - Inhibitors of expression and/or function - Google Patents

Inhibitors of expression and/or function Download PDF

Info

Publication number
WO2024165571A3
WO2024165571A3 PCT/EP2024/052934 EP2024052934W WO2024165571A3 WO 2024165571 A3 WO2024165571 A3 WO 2024165571A3 EP 2024052934 W EP2024052934 W EP 2024052934W WO 2024165571 A3 WO2024165571 A3 WO 2024165571A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
expression
function
disease
disorder associated
Prior art date
Application number
PCT/EP2024/052934
Other languages
French (fr)
Other versions
WO2024165571A2 (en
Inventor
Alan Victor WHITMORE
Sophia MALANDRAKI-MILLER
Ines DE SANTIAGO
Natalie PURSELL
Gaye Saginc GIANNOUSTAS
Original Assignee
E-Therapeutics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E-Therapeutics Plc filed Critical E-Therapeutics Plc
Publication of WO2024165571A2 publication Critical patent/WO2024165571A2/en
Publication of WO2024165571A3 publication Critical patent/WO2024165571A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/343Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to inhibitors, and compositions containing inhibitors, and uses of the same in the treatment or prevention of a metabolic disease or disorder, such as a metabolic disease or disorder associated with non-alcoholic fatty liver disease (NAFLD), and/or obesity and/or a disease or disorder associated with adipogenesis.
PCT/EP2024/052934 2023-02-06 2024-02-06 Inhibitors of expression and/or function WO2024165571A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP23155094 2023-02-06
EP23155094.8 2023-02-06
EP23217288.2 2023-12-15
EP23217288 2023-12-15
EP23219939 2023-12-22
EP23219939.8 2023-12-22

Publications (2)

Publication Number Publication Date
WO2024165571A2 WO2024165571A2 (en) 2024-08-15
WO2024165571A3 true WO2024165571A3 (en) 2024-10-10

Family

ID=89845100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/052934 WO2024165571A2 (en) 2023-02-06 2024-02-06 Inhibitors of expression and/or function

Country Status (1)

Country Link
WO (1) WO2024165571A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005786A2 (en) * 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for enhancing production of a biological product
WO2011084193A1 (en) * 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
WO2012005898A2 (en) * 2010-06-15 2012-01-12 Alnylam Pharmaceuticals, Inc. Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
KR20150086442A (en) * 2014-01-17 2015-07-28 주식회사 바이오인프라 Composition for overcoming resistance to her2 inhibitor comprising ant2 sirna
WO2019051402A1 (en) * 2017-09-11 2019-03-14 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (en) 1992-03-25 1992-03-25 Bernard Thorens PEPTIDE
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
CZ300837B6 (en) 1996-08-30 2009-08-26 Novo Nordisk A/S GLP-1 (7-37) derivatives or analogs thereof, pharmaceutical composition in which the derivatives are comprised as well as their use
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043341A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
ATE466027T1 (en) 1998-02-27 2010-05-15 Novo Nordisk As DERIVATIVES OF GLP-1 ANALOGUE
KR101241862B1 (en) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 Novel glp-1 derivatives
AU2004298425A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 analogues linked to albumin-like agents
WO2005058954A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
AU2005261740A1 (en) 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
EP1799711B1 (en) 2004-10-07 2012-06-20 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
KR20070120112A (en) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 Extended LP-1 Compound
GB0606212D0 (en) 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
JP6017754B2 (en) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Glucagon / GLP-1 receptor co-agonist
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
ES2672770T3 (en) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivatives of glucagon-like peptide-1 and its pharmaceutical use
ES2532116T3 (en) 2007-09-05 2015-03-24 Novo Nordisk A/S Peptides derived with A-B-C-D and their therapeutic uses
GB0724478D0 (en) 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
PE20100056A1 (en) 2008-06-17 2010-01-26 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS AS GIP AGONISTS
CN103641907A (en) 2008-06-17 2014-03-19 印第安纳大学研究及科技有限公司 Glucagon/glp-1 receptor co-agonists
WO2010142665A1 (en) 2009-06-11 2010-12-16 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp GLUCAGON / GLP-I RECEPTOR CO-AGONISTS
AR081975A1 (en) 2010-06-23 2012-10-31 Zealand Pharma As GLUCAGON ANALOGS
WO2012167744A1 (en) 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
US10100097B2 (en) 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
KR20150043505A (en) 2012-09-07 2015-04-22 사노피 Fusion proteins for treating a metabolic syndrome
KR102138750B1 (en) 2012-09-17 2020-07-29 마드리갈 파마슈티칼스, 인크. Method of synthesizing thyroid hormone analogs and polymorphs thereof
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
TWI617574B (en) 2012-12-11 2018-03-11 梅迪繆思有限公司 Glucagon and glp-1 co-agonists for the treatment of obesity
PL2934568T3 (en) 2012-12-21 2018-03-30 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
DK3004155T3 (en) 2013-05-28 2022-01-03 Takeda Pharmaceuticals Co PEPTIME CONNECTION
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
MX369770B (en) 2013-11-06 2019-11-21 Zealand Pharma As Glucagon-glp-1-gip triple agonist compounds.
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
EP3129041B1 (en) 2014-04-07 2019-06-12 Novo Nordisk A/S Double-acylated glp-1 compounds
JOP20200119A1 (en) 2015-01-09 2017-06-16 Lilly Co Eli Gip and glp-1 co-agonist compounds
CN115181175A (en) 2016-04-22 2022-10-14 深圳市图微安创科技开发有限公司 GLP-1R/GCGR dual-target agonist polypeptides for treating fatty liver disease, hyperlipidemia and arteriosclerosis
AR110299A1 (en) 2016-12-02 2019-03-13 Sanofi Sa CONJUGATES UNDERSTANDING A DUAL GLP-1 / GLUCAGON AGONIST, A CONNECTOR AND Hyaluronic Acid
CN110087671A (en) 2016-12-22 2019-08-02 赛诺菲 FGF21 compound/GLP-1R agonist combinations of activity ratio with optimization
CN108570109B (en) 2017-03-14 2022-04-26 广东东阳光药业有限公司 Dual target fusion proteins comprising an immunoglobulin Fc portion
EP3664833B1 (en) 2017-08-09 2023-05-31 Sanofi Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
JP2020535138A (en) 2017-09-25 2020-12-03 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Long-acting coagonists of glucagon and GLP-1 receptors
CN111465773B (en) 2017-12-22 2021-11-02 瓦林格创新股份有限公司 Panel set, method for assembling the panel set and locking device for furniture products
EP3775207A1 (en) 2018-04-05 2021-02-17 Silence Therapeutics GmbH Sirnas with vinylphosphonate at the 5' end of the antisense strand
US20210275643A1 (en) 2018-06-21 2021-09-09 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
CA3107345A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Gip/glp1 co-agonist compounds
MX2022009149A (en) 2020-01-23 2022-12-15 Lilly Co Eli Gip/glp1 co-agonist compounds.
EP4142695A1 (en) 2020-04-29 2023-03-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
TW202216746A (en) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 Long acting glp-1/gip dual agonists
WO2022002408A1 (en) 2020-07-02 2022-01-06 Sanofi Glp-1r agonist / fgf21 fusion proteins
TW202214679A (en) 2020-07-22 2022-04-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1 and gip receptor co-agonists
AU2021361263A1 (en) 2020-10-17 2023-02-16 Sun Pharmaceutical Industries Limited GLP-1/GIP dual agonists
JP2023550594A (en) 2020-10-30 2023-12-04 ノヴォ ノルディスク アー/エス GLP-1, GIP, and glucagon receptor triple agonist
CN115572326B (en) 2021-06-21 2025-01-10 广东东阳光药业股份有限公司 Triple agonist of GLP-1, GCG and GIP receptors
AU2022320922A1 (en) 2021-07-30 2024-01-18 Boehringer Ingelheim International Gmbh Dose regimen for long-acting glp1/glucagon receptor agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011005786A2 (en) * 2009-07-06 2011-01-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for enhancing production of a biological product
WO2011084193A1 (en) * 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
WO2012005898A2 (en) * 2010-06-15 2012-01-12 Alnylam Pharmaceuticals, Inc. Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
KR20150086442A (en) * 2014-01-17 2015-07-28 주식회사 바이오인프라 Composition for overcoming resistance to her2 inhibitor comprising ant2 sirna
WO2019051402A1 (en) * 2017-09-11 2019-03-14 Arrowhead Pharmaceuticals, Inc. Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Material Safety Data Sheet: Adenine Nucleotide Translocator 2 Antibody BIOTIN", 21 April 2021 (2021-04-21), XP093159712, Retrieved from the Internet <URL:https://www.thermofisher.com/document-connect/document-connect.html?url=https://assets.thermofisher.com/TFS-Assets%2FBID%2FSDS%2FANT2-BIOTIN%20MSDS.pdf> *
JANINA-MIRIAM NOY: "Direct Polymerization of the Arsenic Drug PENAO to Obtain Nanoparticles with High Thiol-Reactivity and Anti-Cancer Efficiency", BIOCONJUGATE CHEMISTRY, vol. 29, no. 2, 18 January 2018 (2018-01-18), US, pages 546 - 558, XP093160098, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.8b00032 *
JANITH A. SENEVIRATNE: "Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma", INTERNATIONAL JOURNAL OF CANCER, vol. 152, no. 7, 8 November 2022 (2022-11-08), US, pages 1399 - 1413, XP093159664, ISSN: 0020-7136, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/ijc.34349> DOI: 10.1002/ijc.34349 *
JONG BAE SEO: "Knockdown of ANT2 reduces adipocyte hypoxia and improves insulin resistance in obesity", NATURE METABOLISM, vol. 1, no. 1, 19 November 2018 (2018-11-19), pages 86 - 97, XP093159888, ISSN: 2522-5812, Retrieved from the Internet <URL:https://www.nature.com/articles/s42255-018-0003-x.pdf> DOI: 10.1038/s42255-018-0003-x *
JOONSEOK CHO: "Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance", NATURE COMMUNICATIONS, vol. 8, no. 1, 16 February 2017 (2017-02-16), UK, XP093159877, ISSN: 2041-1723, Retrieved from the Internet <URL:https://www.nature.com/articles/ncomms14477> DOI: 10.1038/ncomms14477 *
LE BRAS MORGANE ET AL: "Chemosensitization by knockdown of adenine nucleotide translocase-2", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 66, no. 18, 15 September 2006 (2006-09-15), pages 9143 - 9152, XP002603476, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-4407 *
LI MING-HSIN ET AL: "Ligand Characteristics Important to Avidity Interactions of Multivalent Nanoparticles", BIOCONJUGATE CHEMISTRY, vol. 28, no. 6, 11 April 2017 (2017-04-11), US, pages 1649 - 1657, XP055917014, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00098 *
SHENGLONG ZHU: "Slc25a5 regulates adipogenesis by modulating ERK signaling in OP9 cells", CELLULAR & MOLECULAR BIOLOGY LETTERS, vol. 27, no. 1, 2 February 2022 (2022-02-02), PL, XP093159660, ISSN: 1425-8153, Retrieved from the Internet <URL:https://link.springer.com/article/10.1186/s11658-022-00314-y/fulltext.html> DOI: 10.1186/s11658-022-00314-y *
TAKAHIRO IKEDA: "Genistein regulates adipogenesis by blocking the function of adenine nucleotide translocase-2 in the mitochondria", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 86, no. 2, 29 November 2021 (2021-11-29), GB, pages 260 - 272, XP093159878, ISSN: 1347-6947, Retrieved from the Internet <URL:https://academic.oup.com/bbb/article-pdf/86/2/260/42565332/zbab203.pdf> DOI: 10.1093/bbb/zbab203 *

Also Published As

Publication number Publication date
WO2024165571A2 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
MX2021009563A (en) Pharmaceutical combination comprising tno155 and ribociclib.
SA521422068B1 (en) GLP-1R Agonists and Uses Thereof
CR20210562A (en) Glp-1r agonists and uses thereof
MY156316A (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
CL2017001983A1 (en) Pharmaceutical compositions for combination therapy.
WO2022109398A9 (en) Oligonucleotides for dgat2 modulation
CO2021001472A2 (en) Transglutaminase 2 (tg2) inhibitors
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
MX2021010350A (en) Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising leuconostoc citreum wikim0104.
AU2018246796A1 (en) S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis
AU2018280875A1 (en) Solid compositions for oral administration
WO2021247885A3 (en) Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
HK1074592A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP2502996A3 (en) Anti-FGF23 antibody and pharmaceutical composition comprising the same
WO2020247701A3 (en) Inhibitors of sarm1
MY177974A (en) A pharmaceutical composition for prevention of diet induced obesity
MX2021010349A (en) Composition for preventing, alleviating, or treating obesity or fatty liver disease, comprising weissella hellenica wikim0103.
PH12019501295A1 (en) Nutritional compositions containing butyrate and/or lactoferrin and uses thereof
MX2022001973A (en) Formulations for prevention or reduction of c. difficile infections.
WO2021158635A8 (en) Anti-viral compositions and methods of use
NZ775294A (en) Aerosolised formulation
MX2023003089A (en) Solid dosage forms of bacteria.
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
WO2024165571A3 (en) Inhibitors of expression and/or function
AU2020378127A8 (en) Compounds as CD73 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24703564

Country of ref document: EP

Kind code of ref document: A2